Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438374 | 1.00 | RAB9A (0.58) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL29438377 | 1.00 | RAB9A (0.58) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL13450604 | 0.98 | RAB9A (0.55) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL8345825 | 0.95 | RAB9A (0.51) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL15256162 | 0.91 | RAB9A (0.50) | RAB9ANPC1PI4KBALDH1A1MAPT | |
| SCHEMBL22532118 | 0.79 | GRM5 (0.44) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19104738 | 0.77 | NPC1 (0.59) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL19381865 | 0.77 | NPC1 (0.59) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL19103059 | 0.77 | NPC1 (0.59) | RAB9ANPC1PI4KBALDH1A1TYR | |
| SCHEMBL13326581 | 0.77 | PRKCI (0.44) | RAB9ANPC1ALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | disclosed |
| EP-1863833-B1 | PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1610776-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1791402-A | Ophthalmic compositions for treating ocular hypertension | MERCK & CO INC (US) | 2006-06-21 | — | — | CN | disclosed |
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | EVOTEC OAI (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1610776-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co. Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004087051-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | PI4KB, CDKN1A, PI4KA | RAB9A 2516/4885NPC1 2972/4885PI4KB 1/4885 |
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | KCNN1, KCNN3, KCNN2 | RAB9A 1480/4885NPC1 275/4885PI4KB 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.